The AIPPI Pharma Committee monitors, comments and advises AIPPI on policy, regulatory and legal frameworks relating to intellectual property protection for pharmaceutical products and processes, diagnostic products and medical devices. The Committee also considers policy initiatives, and best practices for national and regional legislation.


Position paper on the waiver for certain provisions of the TRIPS agreement for the prevention, containment and treatment of COVID-19 proposed by some countries within the WTO.


Terms of Reference.